Research & Development

Our Approach

Therapeutics Development

Our research and development efforts are focused on discovering and developing innovative oncology treatments. Our approach is rooted in scientific excellence and a deep understanding of pancreatic and ovarian cancer.

 

 

On the horizon, in our laboratories, are several additional investigational drugs, each designed to address different aspects of cancer treatment. From early stage discovery to late-stage clinical trials, we are committed to advancing science and technology to bring new therapies to cancer patients.

Our Approach

Our research and development efforts are focused on discovering and developing innovative oncology treatments. Our approach is rooted in scientific excellence and a deep understanding of pancreatic and ovarian cancer.

Therapeutics Development

On the horizon, in our laboratories, are several additional investigational drugs, each designed to address different aspects of cancer treatment. From early stage discovery to late-stage clinical trials, we are committed to advancing science and technology to bring new therapies to cancer patients.

Publications & Presentations

Publications
& Presentations

Stay informed about our latest research findings, publications, and presentations at scientific conferences. We are committed to sharing our research with the scientific community to advance the field of oncology.

Stay informed about our latest research findings, publications, and presentations at scientific conferences. We are committed to sharing our research with the scientific community to advance the field of oncology.

An Inhibitor of GSK3B and
HDACs Kills Pancreatic Cancer
Cells and Slows Pancreatic
Tumor Growth and
Metastasis in Mice

Background & Aims

Growth, progression, and drug resistance of pancreatic
ductal adenocarcinomas (PDACs) have been associated
with increased levels and activity of glycogen synthase
kinase 3 beta (GSK3B) and histone deacetylases (HDACs).
We designed and synthesized molecules that simultaneously
inhibit the activities of both enzymes. We tested the effects
of one of these molecules, AP-001, in pancreatic cancer
cells and mice with pancreatic tumors.

Dual inhibition of GSK3B
and HDACs reduces cancer
cell survival in both human
and mouse ovarian cancer
cell lines.

objective

To investigate the anti-tumor effect of a newly-developed
dual inhibitor (APCS-540) of glycogen synthase kinase 3
beta (GSK3B) and histone deacetylases (HDACs) in
ovarian cancer cells. AP-001, in pancreatic cancer cells
and mice with pancreatic tumors.

AI may detect earliest signs of
pancreatic cancer.

Background

To stratify high-risk individuals for PDAC by identifying
predictive features in pre-diagnostic abdominal Computed
Tomography (CT) scans. pancreatic cancer cells and mice
with pancreatic tumors.

Debiao Li, PhD, Stephen Pandol:
AI and machine learning could
improve cancer diagnosis

overview

Among the promising applications of AI, DL, and ML
presented in this issue are identifying early-stage cancers,
inferring the location of specific cancers, assisting in the
assignment of appropriate therapeutic options for each
patient, characterizing the tumor microenvironment, and
predicting immunotherapy response.lases (HDACs) in
ovarian cancer cells. AP-001, in pancreatic cancer cells and
mice with pancreatic tumors.

AI tools for earlier pancreatic
cancer diagnosis may yield
'increasingly better outcomes'

excerpt

Advances in image acquisition devices, processing tech-
niques and analysis tools also have opened the door for
medical imaging-based AI screening in one of the most
lethal and notoriously difficult-to-detect malignancies —
pancreatic cancer.

An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice

Background & Aims

Growth, progression, and drug resistance of pancreatic ductal adenocarcinomas (PDACs) have been associated with increased levels and activity of glycogen synthase kinase 3 beta (GSK3B) and histone deacetylases (HDACs). We designed and synthesized molecules that simultaneously inhibit the activities of both enzymes. We tested the effects of one of these molecules, AP-001, in pancreatic cancer cells and mice with pancreatic tumors.

Dual inhibition of GSK3B and HDACs reduces cancer cell survival in both human and mouse ovarian cancer cell lines.

Objective

To investigate the anti-tumor effect of a newly-developed dual inhibitor (APCS-540) of glycogen synthase kinase 3 beta (GSK3B) and histone deacetylases (HDACs) in ovarian cancer cells. AP-001, in pancreatic cancer cells and mice with pancreatic tumors.

AI may detect earliest signs of pancreatic cancer.

background

To stratify high risk individuals for PDAC by identifying predictive features in pre-diagnostic abdominal Computed Tomography (CT) scans.pancreatic cancer cells and mice with pancreatic tumors.

Debiao Li, PhD, Stephen Pandol: AI and machine learning could improve cancer diagnosis

Overview

Among the promising applications of AI, DL, and ML presented in this issue are identifying early-stage cancers, inferring the location of specific cancers, assisting in the assignment of appropriate therapeutic options for each patient, characterizing the tumor microenvironment, and predicting immunotherapy response.lases (HDACs) in ovarian cancer cells. AP-001, in pancreatic cancer cells and mice with pancreatic tumors.

AI tools for earlier pancreatic cancer diagnosis may yield ‘increasingly better outcomes’

excerpt

Advances in image acquisition devices, processing techniques and analysis tools also have opened the door for medical imaging-based AI screening in one of the most lethal and notoriously difficult-to-detect malignancies — pancreatic cancer.

Scroll to Top